-- 据周一提交给香港交易所的文件显示，上海复宏汉霖生物技术有限公司（HKG:2696）已获得日本药品和医疗器械管理局的默示批准，将在日本开展注射用HLX43的II/III期临床试验。 该药物正在接受单药治疗或与匹莫妥单抗HLX07联合治疗的临床试验，并与多西他赛进行比较，用于治疗晚期鳞状非小细胞肺癌。 文件称，一旦满足相关条件，公司将启动该试验。
Related Articles
Asia
BOE Varitronix Enters Three-Year Framework Tenancy Contract
BOE Varitronix (HKG:0710) entered into a framework tenancy agreement with BOE Technology Group's (SHE:000725, SHE:200725) for various properties owned by the latter, according to a Monday Hong Kong bourse filing.The term of the contract began May 1, 2026, and will end April 30, 2029, the liquid crystal display manufacturer said.The parties will enter individual tenancy and property service agreements containing details related to the tenancy of specific premises.BOE Technology Group's unit BOE Technology (HK) is BOE Varitronix's substantial shareholder.
$HKG:0710$SHE:000725$SHE:200725
Asia
VVIP Infratech Subsidiary Rebrands to VVIP Realtech
VVIP Infratech (BOM:544219) subsidiary Vibhor Vaibhav Infrahome has changed its name to VVIP Realtech, according to a Monday filing on the BSE.
$BOM:544219
Asia
Hindustan Zinc CFO Resigns
Hindustan Zinc's (NSE:HINDZINC, BOM:500188) chief financial officer, Sandeep Modi, has resigned to pursue opportunities outside the company, according to a Monday filing on Indian bourses.The resignation will be effective May 30, the filing said.
$BOM:500188$NSE:HINDZINC